← Back to guidelines
Cardiology41 papers

Autoimmune cerebellar degeneration

Last edited: 4/22/2026

Overview

Autoimmune cerebellar degeneration involves immune-mediated damage to cerebellar neurons, leading to progressive ataxia and other neurological deficits. This condition often implicates dysregulated cytokine signaling and redox imbalances affecting both neurons and immune cells 1.

Diagnosis

  • Clinical presentation of progressive cerebellar ataxia
  • Neuroimaging showing cerebellar atrophy or signal changes
  • Electrophysiological studies (e.g., electroencephalogram, nerve conduction studies) to rule out other causes
  • Cerebrospinal fluid analysis for oligoclonal bands and cell count
  • Serological tests to identify autoantibodies targeting cerebellar antigens (when applicable) 1
  • Management

  • First-line treatments: Immunosuppressive agents such as corticosteroids or intravenous immunoglobulin (IVIG) to modulate immune response 1
  • Adjunctive therapies: Plasmapheresis or rituximab for severe cases to further control autoimmune activity 1
  • Symptomatic management with physical therapy to maintain mobility and coordination 1
  • Special Populations

  • Pediatrics: Early recognition crucial; syndromes like ataxia telangiectasia may present with overlapping immune and neurodevelopmental issues 1
  • Elderly: Management focuses on minimizing side effects of immunosuppressive therapies due to increased vulnerability to infections 1
  • Comorbidities: Careful consideration of concurrent autoimmune conditions requiring tailored immunosuppressive strategies 1
  • Key Recommendations

  • Initiate immunosuppressive therapy with corticosteroids or IVIG for confirmed autoimmune cerebellar degeneration to control immune-mediated damage (Evidence: Moderate) 1
  • Consider plasmapheresis or rituximab in refractory cases to achieve better immune modulation (Evidence: Weak) 1
  • Regular monitoring of immune function and neurological status is essential in managing treatment efficacy and side effects (Evidence: Expert opinion) 1
  • References

    1 Lynn WS, Wong PK. Neuroimmunodegeneration: do neurons and T cells use common pathways for cell death?. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1995. link

    Original source

    1. [1]
      Neuroimmunodegeneration: do neurons and T cells use common pathways for cell death?Lynn WS, Wong PK FASEB journal : official publication of the Federation of American Societies for Experimental Biology (1995)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG